

DAFTAR PUSTAKA

- Abubakar, A., Simbak, N., dan Haque, M., 2014. Adverse Drug Reactions: Predisposing Factors, Modern Classifications and Causality Assessment. *Research Journal of Pharmacy and Technology*, **7**: .
- Alimohamadi, Y., Yekta, E.M., Sepandi, M., Sharafoddin, M., Arshadi, M., dan Hesari, E., 2022. Hospital length of stay for COVID-19 patients: a systematic review and meta-analysis. *Multidisciplinary Respiratory Medicine*, **17**: 856.
- Allredge, B.K., Corelli, R.L., Ernst, M.E., Guglielmo, B.J., dan Jacobson, P.A. (Editor), 2012. *Koda-Kimble & Young's Applied Therapeutics: The Clinical Use of Drugs*, 10th edition. ed. Lippincott Williams & Wilkins, Philadelphia.
- Almadhoun, K. dan Sharma, S., 2022. Bronchodilators, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Alomar, M.J., 2014. Factors affecting the development of adverse drug reactions (Review article). *Saudi Pharmaceutical Journal : SPJ*, **22**: 83–94.
- Alshehail, B., Al Jamea, Z., Chacko, R., Alotaibi, F., Ismail, N., dan Alshayban, D., 2022. Incidence and risk factors of adverse drug reactions in patients with coronavirus disease 2019: A pharmacovigilance experience utilizing an ADR trigger tool. *Saudi Pharmaceutical Journal : SPJ*, **30**: 407–413.
- Alvim, M.M., da Silva, L.A., Leite, I.C.G., dan Silvério, M.S., 2015. Adverse events caused by potential drug-drug interactions in an intensive care unit of a teaching hospital. *Revista Brasileira de Terapia Intensiva*, **27**: 353–359.
- American Diabetes Association, 2021. Glycemic Targets: Standards of Medical Care in Diabetes. *Diabetes Care*, **44**: S73–S84.
- Andrews, P.L.R., Cai, W., Rudd, J.A., dan Sanger, G.J., 2021. COVID-19, nausea, and vomiting. *Journal of Gastroenterology and Hepatology*, **36**: 646–656.
- Armon, D.B., Fine, N.B., Seligman, Z., Ginzburg, K., dan Ben-Zion, Z., 2021. COVID-19 epidemic-induced changes in mood and anxiety mediate the relationship between resilience and symptoms of depression and generalized anxiety in sexual assault survivors. *Journal of Affective Disorders Reports*, **6**: 100252.
- Asyrof, A., Arisdiani, T., dan Aspihan, M., 2021. Karakteristik dan kualitas hidup pasien Penyakit Paru Obstruksi Konik (PPOK). *NURSCOPE: Jurnal Penelitian dan Pemikiran Ilmiah Keperawatan*, **7**: 13–21.
- Baj, J., Karakuła-Juchnowicz, H., Teresiński, G., Buszewicz, G., Ciesielka, M., Sitarz, R., dkk., 2020. COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge. *Journal of Clinical Medicine*, **9**: 1753.
- Barnes, G.D., 2020. Combining antiplatelet and anticoagulant therapy in cardiovascular disease. *Hematology*, **2020**: 642–648.

- Bebitoğlu, B.T., Oğuz, E., Nuhoglu, Ç., Dalkılıç, A.E.K., Çirtlik, P., Temel, F., dkk., 2020. Evaluation of potential drug-drug interactions in a pediatric population. *Turkish Archives of Pediatrics/Türk Pediatri Arşivi*, **55**: 30–38.
- Ben Salem, C., Fathallah, N., Hmouda, H., dan Bouraoui, K., 2011. Drug-Induced Hypoglycaemia. *Drug Safety*, **34**: 21–45.
- Ben Salem, C., Slim, R., Fathallah, N., dan Hmouda, H., 2017. Drug-induced hyperuricaemia and gout. *Rheumatology*, **56**: 679–688.
- Bergs, I., Just, K.S., Scholl, C., Dreher, M., dan Stingl, J.C., 2023. Inhalation therapies in COPD — adverse drug reactions impact on emergency department presentations. *European Journal of Clinical Pharmacology*, **79**: 219.
- Bhuvaneshwari, s, Vel, P., Vijaya, D., Sowmya, M., dan Kumar, R., 2018. Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study. *Journal of Clinical and Diagnostic Research*, **12**: FC01–FC03.
- BNF, 2020. *British National Formulary 79 March 2020*, 79th ed.
- BPOM dan JICA, 2020. *Modul Farmakovigilans Bagi Tenaga Profesional Kesehatan Proyek “Ensuring drug and food safety.”* Badan POM bekerja sama dengan dukungan JICA (Japan International Cooperation Agency).
- Brandariz-Nuñez, D., Correas-Sanahuja, M., Guarca, E., Picón, R., García, B., dan Gil, R., 2020. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir. *Medicina Clinica (English Ed.)*, **155**: 281–287.
- Burhan, E., Susanto, A.D., Nasution, S.A., Ginanjar, E., Pitoyo, W., Susilo, A., dkk., 2020. Pedoman Tatalaksana COVID 19 Edisi 3 2020 149.
- Buxeda, A., Arias-Cabrales, C., Pérez-Sáez, M.J., Cacho, J., Cabello Pelegrin, S., Melilli, E., dkk., 2021. Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. *Kidney International Reports*, **6**: 2305–2315.
- Cantudo-Cuenca, M.D., Gutiérrez-Pizarra, A., Pinilla-Fernández, A., Contreras-Macias, E., Fernández-Fuertes, M., Lao-Domínguez, F.A., dkk., 2021. Drug–drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. *Scientific Reports*, **11**: 12414.
- Carbon, C., 2001. Levofloxacin adverse effects, data from clinical trials and pharmacovigilance. *Therapie*, **56**: 35–40.
- Cascorbi, I., 2012. Drug interactions--principles, examples and clinical consequences. *Deutsches Arzteblatt international*, **109**: 546–55; quiz 556.
- Cazzola, M., Ora, J., Bianco, A., Rogliani, P., dan Matera, M.G., 2021. Management of COPD patients during COVID: difficulties and experiences. *Expert Review of Respiratory Medicine*, **15**: 1025–1033.
- CDC, 2019. 'Antiviral Adverse Events', . URL: <https://www.cdc.gov/flu/professionals/antivirals/antiviral-adverse-events.htm> (diakses tanggal 4/2/2023).

- Charan, J., Dutta, S., Kaur, R., Bhardwaj, P., Sharma, P., Ambwani, S., dkk., 2021. Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database. *Expert Opinion on Drug Safety*, 1–12.
- Charan, J., Kaur, R.J., Bhardwaj, P., Haque, M., Sharma, P., Misra, S., dkk., 2020. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. *Expert Review of Clinical Pharmacology*, 1–9.
- Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., dkk., 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet (London, England)*, **395**: 507–513.
- Chun, S.Y., Kim, H.J., dan Kim, H.B., 2022. The effect of COVID-19 pandemic on the length of stay and outcomes in the emergency department. *Clinical and Experimental Emergency Medicine*, **9**: 128–133.
- Coleman, J.J. dan Pontefract, S.K., 2016. Adverse drug reactions. *Clinical Medicine*, **16**: 481–485.
- Crescioli, G., Brilli, V., Lanzi, C., Burgalassi, A., Ieri, A., Bonaiuti, R., dkk., 2021. Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug–drug interactions. *Internal and Emergency Medicine*, **16**: 697–710.
- Cuculi, F., Suter, A., dan Erne, P., 2007. Spironolactone-induced gynecomastia. *CMAJ*, **176**: 620-a.
- Dobrivoje, S., Radica, Z.Z., Slobodan, J., Zorica, L., Ivan, C., dan Romana, S., 2020. Risk factors for potential drug-drug interactions in patients with chronic obstructive pulmonary disease. *Irish journal of medical science*, **189**: .
- Docherty, A.B., Harrison, E.M., Green, C.A., Hardwick, H.E., Pius, R., Norman, L., dkk., 2020. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *The BMJ*, **369**: m1985.
- Dong, G., Du, Z., Zhu, J., Guo, Y., Gao, W., Guo, W., dkk., 2021. The clinical characteristics and prognosis of COVID-19 patients with comorbidities: a retrospective analysis of the infection peak in Wuhan. *Annals of Translational Medicine*, **9**: 280.
- Echeverría-Esnal, D., Martin-Ontiyuelo, C., Navarrete-Rouco, M.E., De-Antonio Cuscó, M., Ferrández, O., Horcajada, J.P., dkk., 2021. Azithromycin in the treatment of COVID-19: a review. *Expert Review of Anti-infective Therapy*, **19**: 147–163.
- Edwards, I.R. dan Aronson, J.K., 2000. Adverse drug reactions: definitions, diagnosis, and management. *Lancet (London, England)*, **356**: 1255–1259.
- Efriza, E., 2021. COVID-19. *Baiturrahmah Medical Journal*, **1**: 60–68.

- Egbonu, F., Antonio, F.A., dan Edavalath, M., 2014. Effect of Inhaled Corticosteroids on Glycemic Status. *The Open Respiratory Medicine Journal*, **8**: 101–105.
- Ejaz, H., Alsrhani, A., Zafar, A., Javed, H., Junaid, K., Abdalla, A.E., dkk., 2020. COVID-19 and comorbidities: Deleterious impact on infected patients. *Journal of Infection and Public Health*, **13**: 1833–1839.
- Ergür, F.Ö., Yıldız, M., Şener, M.U., Kavurgacı, S., dan Ozturk, A., 2022. Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study. *São Paulo Medical Journal*, **140**: 372–377.
- Fahmia, R., Helda, H., dan Nursari, A.Y., 2022. Lama Rawat Inap Pasien Terkonfirmasi COVID-19 di Rumah Sakit Universitas Indonesia dan Faktor yang Mempengaruhinya. *Jurnal Epidemiologi Kesehatan Indonesia*, **6**: .
- Faizah, A., Nurrahman, N., dan Putra, O., 2020. A Mini Review : Clinically Significant Potential Drug-Drug Interactions In COVID-19 and Comorbid Therapy. *Pharmaceutical Sciences and Research*, **7**: .
- Fathallah, N., Slim, R., Larif, S., Hmouda, H., dan Ben Salem, C., 2015. Drug-Induced Hyperglycaemia and Diabetes. *Drug Safety*, **38**: 1153–1168.
- Forootan, M., Bagheri, N., dan Darvishi, M., 2018. Chronic constipation. *Medicine*, **97**: e10631.
- Gallelli, L., Ferreri, G., Colosimo, M., Pirritano, D., Flocco, M.A., Pelaia, G., dkk., 2003. Retrospective analysis of adverse drug reactions to bronchodilators observed in two pulmonary divisions of Catanzaro, Italy. *Pharmacological Research*, **47**: 493–499.
- Ganda, O.P., 2016. Statin-induced diabetes: incidence, mechanisms, and implications. *F1000Research*, **5**: F1000 Faculty Rev-1499.
- Gandham, R., Eerike, M., Raj, G.M., Bisoi, D., Priyadarshini, R., dan Agarwal, N., 2022. Adverse events following remdesivir administration in moderately ill COVID-19 patients - A retrospective analysis. *Journal of Family Medicine and Primary Care*, **11**: 3693–3698.
- Gatti, M., Fusaroli, M., Caraceni, P., Poluzzi, E., De Ponti, F., dan Raschi, E., 2021. Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19. *British Journal of Clinical Pharmacology*, **87**: 1533–1540.
- Gentry, S. dan Gentry, B., 2017. Chronic Obstructive Pulmonary Disease: Diagnosis and Management. *American Family Physician*, **95**: 433–441.
- Giardina, C., Cutroneo, P.M., Mocciaro, E., Russo, G.T., Mandraffino, G., Basile, G., dkk., 2018. Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. *Frontiers in Pharmacology*, **9**: .
- Gil, H.-I., Zo, S., Jones, P.W., Kim, B.-G., Kang, N., Choi, Y., dkk., 2021. <p>Clinical Characteristics of COPD Patients According to COPD Assessment Test (CAT) Score Level: Cross-Sectional Study</p>.

- International Journal of Chronic Obstructive Pulmonary Disease*, **16**: 1509–1517.
- Gil-del-Valle, L., Gravier-Hernández, R., Baldoquin-Rodríguez, W., Sierra-Vázquez, B., Perez-Díaz, A.B., Sariol-Resik, P., dkk., 2023. Adverse Drug Reactions during COVID-19 Treatment: A Comprehensive Analysis Focused on Hospitalized Patients, with the Use of a Survey in Cuba in 2020. *Advances in Pharmacological and Pharmaceutical Sciences*, **2023**: 1995642.
- Gold, 2020. *Global Strategy for The Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2020 Report)*. In: *Global Initiative for Chronic Obstructive Lung Disease, Inc.*
- Guo, A., Lu, J., Tan, H., Kuang, Z., Luo, Y., Yang, T., dkk., 2021. Risk factors on admission associated with hospital length of stay in patients with COVID-19: a retrospective cohort study. *Scientific Reports*, **11**: 7310.
- Gupta, R. dan Wadhwa, R., 2022. Mucolytic Medications. *StatPearls*, .
- Hanlon, P., Nicholl, B.I., Jani, B.D., McQueenie, R., Lee, D., Gallacher, K.I., dkk., 2018. Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study. *BMJ Open*, **8**: e018404.
- Hu, B., Guo, H., Zhou, P., dan Shi, Z.-L., 2021. Characteristics of SARS-CoV-2 and COVID-19. *Nature Reviews Microbiology*, **19**: 141–154.
- Huang, B., Chen, Z., Sidell, M., Eckel, S., Martinez, M., Lurmann, F., dkk., 2021. Associations of Asthma, COPD and Medication History with the Risk of Severe COVID-19. *Journal of Allergy and Clinical Immunology*, **147**: AB247.
- Huynh, G. dan Reinert, J.P., 2021. Pharmacological Management of Steroid-Induced Psychosis: A Review of Patient Cases. *The Journal of Pharmacy Technology : jPT : Official Publication of the Association of Pharmacy Technicians*, **37**: 120–126.
- Hwang, J.L. dan Weiss, R.E., 2014. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. *Diabetes/metabolism research and reviews*, **30**: 96–102.
- Ichsan, M.N., Kusadhiani, I., dan Latuconsina, V.Z., 2022. Hubungan Komorbid Dengan Durasi Perawatan Pasien Covid-19 Pada Rs Bayangkara Dan Rs Tk. II Prof. Dr. Ja. Latumeten Di Kota Ambon Tahun 2020. *Molucca Medica*, **15**: 29–40.
- Igho-Osagie, E., Puenpatom, A., Williams, M.G., Song, Y., Yi, D., Wang, J., dkk., 2023. Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy. *Journal of Managed Care & Specialty Pharmacy*, **29**: 10.18553/jmcp.2023.22366.
- In, J., 2017. Introduction of a pilot study. *Korean Journal of Anesthesiology*, **70**: 601.

- Jani, B. dan Marsicano, E., 2018. Constipation: Evaluation and Management. *Missouri Medicine*, **115**: 236–240.
- John R. Horn, P. dan Philip D. Hansten, P., 2015. Anticholinergic Drug Interactions. July 2015 Digestive Health **81**: .
- Joszt, 2018. 'Patients With COPD Face High Risk of Adverse Drug Reactions Due to Multimorbidity', *AJMC*. URL: <https://www.ajmc.com/view/patients-with-copd-face-high-risk-of-adverse-drug-reactions-due-to-multimorbidity> (diakses tanggal 6/2/2023).
- Kamel, A.M., Monem, M.S.A., Sharaf, N.A., Magdy, N., dan Farid, S.F., 2022. Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials. *Reviews in Medical Virology*, **32**: e2258.
- Kaufman, G., 2016. Adverse drug reactions: classification, susceptibility and reporting. *Nursing Standard (Royal College of Nursing (Great Britain): 1987)*, **30**: 53–63.
- Kaur, R.J., Charan, J., Dutta, S., Sharma, Paras, Bhardwaj, P., Sharma, Praveen, dkk., 2020. Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database. *Infection and Drug Resistance*, **13**: 4427–4438.
- Keche, Y., Gaikwad, N., dan Dhaneria, S., 2021. Preventability, predictability, severity and causality assessment of adverse drug reactions reported from a teaching hospital in chhattisgarh: A retrospective analysis. *Journal of Family Medicine and Primary Care*, **10**: 2541.
- Kellum, J.A., 2015. Diagnostic Criteria for Acute Kidney Injury: Present and Future. *Critical care clinics*, **31**: 621–632.
- Kemenkes, 2020a. *Pedoman Pencegahan Dan Pengendalian Coronavirus Disese (Covid-19) Revisi Ke-5*. Kementerian Kesehatan RI, Jakarta.
- Kemenkes, 2020b. Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/413/2020 Tentang Pedoman Pencegahan Dan Pengendalian Coronavirus Disease 2019 (Covid-19).
- Kementrian Kesehatan, R., 2021. *Buku Saku Protokol Tatalaksana COVID-19*, 2nd ed.
- Khalil, H. dan Huang, C., 2020. Adverse drug reactions in primary care: a scoping review. *BMC Health Services Research*, **20**: 5.
- Khan, F., Ismail, M., Khan, Q., dan Ali, Z., 2018. Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review. *Expert Opinion on Drug Safety*, **17**: 1029–1039.
- Khoshnood, S., Shirani, M., Dalir, A., Moradi, M., Haddadi, M.H., Sadeghifard, N., dkk., 2022. Antiviral effects of azithromycin: A narrative review. *Biomedicine & Pharmacotherapy*, **147**: 112682.
- Kim, K.S., Choi, Y.H., Moon, A., dan Kim, S.G., 2020. Body Weight as a Determining Factor in the Predominance of Adverse Drug Reactions

- Induced by Fixed-Dose Adalimumab Injections in Female Patients in a Korean Hospital Setting. *Journal of Clinical Medicine*, **9**: 461.
- Krogager, M.L., Kragholm, K., Thomassen, J.Q., Søgaaard, P., Lewis, B.S., Wassmann, S., dkk., 2021. Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. *European Heart Journal - Cardiovascular Pharmacotherapy*, **7**: 557–567.
- Lee, J., Kim, J., Kang, J., dan Lee, H.J., 2022. COVID-19 drugs: potential interaction with ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. *Journal of Pharmaceutical Investigation*, 1–22.
- Lee, J.Y., Ang, A.S.Y., Mohd Ali, N., Ang, L.M., dan Omar, A., 2021. Incidence of adverse reaction of drugs used in COVID-19 management: a retrospective, observational study. *Journal of Pharmaceutical Policy and Practice*, **14**: 84.
- Lemaitre, F., Solas, C., Grégoire, M., Lagarce, L., Elens, L., Polard, E., dkk., 2020. Potential drug–drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. *Fundamental & Clinical Pharmacology*, **34**: 530–547.
- Lemeshow, S. (Editor), 1990. *Adequacy of Sample Size in Health Studies*. Published on behalf of the World Health Organization by Wiley ; Distributed in the U.S.A., Canada, and Japan by Liss, Chichester [England] ; New York : New York, NY, USA.
- Leung, J.M., Niikura, M., Yang, C.W.T., dan Sin, D.D., 2020. COVID-19 and COPD. *European Respiratory Journal*, **56**: .
- Levani, Y., Prastya, A.D., dan Mawaddatunnadila, S., 2021. Coronavirus Disease 2019 (COVID-19): Patogenesis, Manifestasi Klinis dan Pilihan Terapi. *Jurnal Kedokteran dan Kesehatan*, **17**: 44–57.
- Li, M. dan Ramos, L.G., 2017. Drug-Induced QT Prolongation And Torsades de Pointes. *Pharmacy and Therapeutics*, **42**: 473–477.
- Liamis, G., Liberopoulos, E., Barkas, F., dan Elisaf, M., 2014. Diabetes mellitus and electrolyte disorders. *World Journal of Clinical Cases : WJCC*, **2**: 488–496.
- Liamis, G., Milionis, H., dan Elisaf, M., 2008. A Review of Drug-Induced Hyponatremia. *American Journal of Kidney Diseases*, **52**: 144–153.
- Lin, Z., Wong, L.Y.F., dan Cheung, B.M.Y., 2022. Diuretic-induced hypokalaemia: an updated review. *Postgraduate Medical Journal*, **98**: 477–482.
- Mahboobipour, A.A. dan Baniyadi, S., 2021. Clinically important drug–drug interactions in patients admitted to hospital with COVID-19: drug pairs, risk factors, and management. *Drug Metabolism and Personalized Therapy*, **36**: 9–16.

- Manjhi, P.K., Kumar, R., Priya, A., dan Rab, I., 2021. Drug-Drug Interactions in Patients with COVID-19: A Retrospective Study at a Tertiary Care Hospital in Eastern India. *Mædica*, **16**: 163–169.
- Mannhart, D., Hennings, E., Lischer, M., Vernier, C., Du Fay de Lavallaz, J., Knecht, S., dkk., 2022. Clinical Validation of Automated Corrected QT-Interval Measurements From a Single Lead Electrocardiogram Using a Novel Smartwatch. *Frontiers in Cardiovascular Medicine*, **9**: .
- Marcello, R.K., Dolle, J., Grami, S., Adule, R., Li, Z., Tatem, K., dkk., 2020. Characteristics and outcomes of COVID-19 patients in New York City's public hospital system. *PLoS ONE*, **15**: .
- Marins, T.A., Marra, A.R., Edmond, M.B., Colombo, L.R.P., Vieira, S.F., Xavier, F. de O., dkk., 2021. Adverse drug reactions and drug interactions in the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). *Antimicrobial Stewardship & Healthcare Epidemiology*, **1**: e38.
- Martinez-Lopez, A., Cuenca-Barrales, C., Montero-Vilchez, T., Molina-Leyva, A., dan Arias-Santiago, S., 2020. Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist. *Journal of the American Academy of Dermatology*, **83**: 1738–1748.
- Massachusetts, M.L., PharmD Candidate 2022 Western New England University College of Pharmacy &. Health Sciences Nicole Covill, PharmD Candidate 2022 Western New England University College of Pharmacy &. Health Sciences Marissa L. Ostroff, PharmD, BCPS, BCGP Clinical Associate Professor Department of Pharmacy Practice Western New England University College of Pharmacy &. Health Sciences Springfield, Massachusetts Jared L. Ostroff, PharmD, MBA, BCACP, BCGP Clinical Pharmacy Coordinator Baystate Health-Department of Acute Care Pharmacy Services Springfield, 2021. 'Summarizing the 2021 Updated GOLD Guidelines for COPD', . URL: <https://www.uspharmacist.com/article/summarizing-the-2021-updated-gold-guidelines-for-copd-1> (diakses tanggal 4/2/2023).
- Mathew, T.K., Zubair, M., dan Tadi, P., 2023. Blood Glucose Monitoring, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- McQuade, B.M. dan Campbell, A., 2021. Drug Prescribing: Drug-Drug Interactions. *FP essentials*, **508**: 25–32.
- Miediegha, O. dan Bunu, S., 2020. Pharmacovigilance Framework And Extent Of Medications Adverse Reaction Surveillance In Southern Nigeria. *World Journal of Pharmaceutical Research*, **9**: 2009–2017.
- Miller, N.E., Rushlow, D., dan Stacey, S.K., 2023. Diagnosis and Management of Sodium Disorders: Hyponatremia and Hypernatremia. *American Family Physician*, **108**: 476–486.
- Moon, S.W., Leem, A.Y., Kim, Y.S., Lee, J.-H., Kim, T.-H., Oh, Y.-M., dkk., 2020. Low serum lymphocyte level is associated with poor exercise capacity and

- quality of life in chronic obstructive pulmonary disease. *Scientific Reports*, **10**: 11700.
- Moorthy, N., Raghavendra, N., dan Venkatarathnamma, P.N., 2008. Levofloxacin-induced acute psychosis. *Indian Journal of Psychiatry*, **50**: 57–58.
- Morales-Ríos, O., Jasso-Gutiérrez, L., Reyes-López, A., Garduño-Espinosa, J., dan Muñoz-Hernández, O., 2018. Potential drug-drug interactions and their risk factors in pediatric patients admitted to the emergency department of a tertiary care hospital in Mexico. *PLOS ONE*, **13**: e0190882.
- Murali, M., Suppes, S., Feldman, K., dan Goldman, J., 2021. Utilization of the Naranjo scale to evaluate adverse drug reactions at a free-standing children's hospital. *PLOS ONE*, **16**: e0245368.
- Naughton, C.A., 2008. Drug-Induced Nephrotoxicity. *American Family Physician*, **78**: 743–750.
- Negara, I.N.A.K., Budhitresna, A.A.G., dan Sari, N.L.P.E.K., 2022. Hubungan Antara Komorbiditas Dengan Derajat Keparahan Infeksi Covid-19 Di Rumah Sakit Sanjiwani Gianyar **2**: 13–20.
- Patton, K. dan Borshoff, D.C., 2018. Adverse drug reactions. *Anaesthesia*, **73**: 76–84.
- PDPI, 2021. *Panduan Umum Praktik Klinis Penyakit Paru Dan Pernafasan*. Perhimpunan Dokter Paru Indonesia.
- PDPI, 2023. *Penyakit Paru Obstruktif Kronik (PPOK) Pedoman Diagnosis Dan Penatalaksanaan Di Indonesia*. Perhimpunan Dokter Paru Indonesia, Jakarta.
- PDPI, PERKI, PAPDI, PERDATIN, dan IDAI, 2022. *Pedoman Tatalaksana Covid-19*, 4th ed. Diterbitkan bersama Perhimpunan Dokter Paru Indonesia. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia. Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia. Ikatan Dokter Anak Indonesia.
- Perazella, M.A. dan Rosner, M.H., 2022. Drug-Induced Acute Kidney Injury. *Clinical Journal of the American Society of Nephrology*, **17**: 1220.
- Perhimpunan Dokter Paru Indonesia, 2003. *Penyakit Paru Obstruktif Kronik (PPOK) : Pedoman Diagnosis Dan Penatalaksanaan Di Indonesia*.
- Pourbagheri-Sigaroodi, A., Bashash, D., Fateh, F., dan Abolghasemi, H., 2020. Laboratory findings in COVID-19 diagnosis and prognosis. *Clinica Chimica Acta; International Journal of Clinical Chemistry*, **510**: 475–482.
- Punyaratabandhu, P. dan Vanitchpongphan, S., 2022. Favipiravir-induced cutaneous adverse reactions in patients infected with COVID-19. *Clinical and Experimental Dermatology*, **47**: 573–577.
- Putra, I.P.W. dan Artika, I.D.M., 2013. Chronic Obstructive Pulmonary Disease, Diagnosis And Treatment. *E-Jurnal Medika Udayana*, 53–69.
- Radwan, N.M., Mahmoud, N.E., Alfaifi, A.H., dan Alabdulkareem, K.I., 2020. Comorbidities and severity of coronavirus disease 2019 patients. *Saudi Medical Journal*, **41**: 1165–1174.

- Rahayu, T., Maulidia, Z., dan Faridah, I., 2022. Pengaruh Slow Deep Breathing Terhadap Fatigue Pada Pasien Dengan Ppok Di Rsud Malingping. *Jurnal Locus Penelitian dan Pengabdian*, **1**: 764–772.
- Rahmadani, I.D., Irawati, S., Wibowo, Y.I., dan Setiadi, A.P., 2023. Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities. *PeerJ*, **11**: e15072.
- Rees, E.M., Nightingale, E.S., Jafari, Y., Waterlow, N.R., Clifford, S., B. Pearson, C.A., dkk., 2020. COVID-19 length of hospital stay: a systematic review and data synthesis. *BMC Medicine*, **18**: 270.
- Rehman, A., Setter, S.M., dan Vue, M.H., 2011. Drug-Induced Glucose Alterations Part 2: Drug-Induced Hyperglycemia. *Diabetes Spectrum*, **24**: 234–238.
- Restrepo, M.I., Sibila, O., dan Anzueto, A., 2018. Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. *Tuberculosis and Respiratory Diseases*, **81**: 187–197.
- Roblek, T., Trobec, K., Mrhar, A., dan Lainscak, M., 2014. Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease. *Archives of Medical Science : AMS*, **10**: 920.
- Rocca, E., Gauffin, O., Savage, R., Vidlin, S.H., dan Grundmark, B., 2021. Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020. *Drug Safety*, **44**: 987–998.
- Rogliani, P., Ritondo, B.L., Zerillo, B., Matera, M.G., dan Calzetta, L., 2021. Drug interaction and chronic obstructive respiratory disorders. *Current Research in Pharmacology and Drug Discovery*, **2**: 100009.
- Sanyaolu, A., Okorie, C., Marinkovic, A., Patidar, R., Younis, K., Desai, P., dkk., 2020. Comorbidity and its Impact on Patients with COVID-19. *Sn Comprehensive Clinical Medicine*, **2**: 1069–1076.
- Sarkar, M., Rajta, P.N., dan Khatana, J., 2015. Anemia in Chronic obstructive pulmonary disease: Prevalence, pathogenesis, and potential impact. *Lung India : Official Organ of Indian Chest Society*, **32**: 142–151.
- Shetty, V., Chowta, M.N., Chowta K, N., Shenoy, A., Kamath, A., dan Kamath, P., 2018. Evaluation of Potential Drug-Drug Interactions with Medications Prescribed to Geriatric Patients in a Tertiary Care Hospital. *Journal of Aging Research*, **2018**: 5728957.
- Singh, A. dan Kamath, A., 2021. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data. *Expert Opinion on Drug Safety*, **20**: 1559–1564.
- Singh, D., Mathioudakis, A.G., dan Higham, A., 2022. Chronic obstructive pulmonary disease and COVID-19: interrelationships. *Current Opinion in Pulmonary Medicine*, **28**: 76–83.
- Singh, P., Yoon, S.S., dan Kuo, B., 2016. Nausea: a review of pathophysiology and therapeutics. *Therapeutic Advances in Gastroenterology*, **9**: 98–112.
- Spanakis, M., Ioannou, P., Tzalis, S., Chouzouri, F., Patelarou, E., Kofteridis, D.P., dkk., 2023. Evaluation of Drug Interactions in Hospitalized Patients with

- Respiratory Disorders in Greece. *Advances in Respiratory Medicine*, **91**: 74–92.
- Stojadinovic, D., Zivkovic Zaric, R., Jankovic, S., Lazic, Z., Cekerevac, I., dan Susa, R., 2020. Risk factors for potential drug-drug interactions in patients with chronic obstructive pulmonary disease. *Irish Journal of Medical Science (1971 -)*, **189**: 1123–1125.
- Sun, J., Deng, X., Chen, X., Huang, J., Huang, S., Li, Y., dkk., 2020. Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System. *Clinical Pharmacology and Therapeutics*, **108**: 791.
- Tagboto, S., 2022. Severe Electrolyte Disturbances Due to Proton Pump Inhibitor Therapy: An Underrecognized Problem with Potentially Severe Sequelae. *The American Journal of Case Reports*, **23**: e936893-1-e936893-5.
- TeBay, C., Hill, A.P., dan Windley, M.J., 2022. Metabolic and electrolyte abnormalities as risk factors in drug-induced long QT syndrome. *Biophysical Reviews*, **14**: 353–367.
- Tisdale, J.E., Chung, M.K., Campbell, K.B., Hammadah, M., Joglar, J.A., Leclerc, J., dkk., 2020. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. *Circulation*, **142**: e214–e233.
- Trustman, N., 2014. Apakah Moxifloxacin Meningkatkan Risiko Disglikemia? | Pos Rho Chi.
- Turan, O., Arpinar Yigitbas, B., Turan, P.A., dan Mirici, A., 2021. Clinical characteristics and outcomes of hospitalized COVID-19 patients with COPD. *Expert Review of Respiratory Medicine*, 1–8.
- Veltri, K.T. dan Mason, C., 2015. Medication-Induced Hypokalemia. *Pharmacy and Therapeutics*, **40**: 185–190.
- Walter, S.R., Day, R.O., Gallego, B., dan Westbrook, J.I., 2017. The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia. *British Journal of Clinical Pharmacology*, **83**: 416–426.
- Wang, Y., Xu, J., Meng, Y., Adcock, I.M., dan Yao, X., 2018. Role of inflammatory cells in airway remodeling in COPD. *International Journal of Chronic Obstructive Pulmonary Disease*, **13**: 3341–3348.
- Whitehead, A., Julious, S., Cooper, C., dan Campbell, M., 2015. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. *Statistical methods in medical research*, **25**: .
- Wittes, J. dan Brittain, E., 1990. The role of internal pilot studies in increasing the efficiency of clinical trials. *Statistics in Medicine*, **9**: 65–71; discussion 71–72.
- Wung, S.-F., 2016. Bradyarrhythmias: Clinical Presentation, Diagnosis, and Management. *Critical Care Nursing Clinics of North America*, , Cardiac Arrhythmias **28**: 297–308.

- Yibirin, M., De Oliveira, D., Valera, R., Plitt, A.E., dan Lutgen, S., 2021. Adverse Effects Associated with Proton Pump Inhibitor Use. *Cureus*, **13**: e12759.
- Yuniar, Y., Ramadhiani, A.R., Asyifa, D., Putri, W.K.A., dan Apriliana, W.S., 2022. Potensi Interaksi Obat Pada Pasien Covid-19 Terkonfirmasi Dengan Komorbid di Bangsal Ogan RSUP Dr. Mohammad Hoesin Palembang Periode April-Juni 2021. *Majalah Farmaseutik*, **18**: 43–50.
- Zaenab, A., Jose, V., Cynthia, C.-J., Yousuf, Z., Claudia, M., dan Hamed, S., 2021. The Effects of Co-morbidities on COVID-19 Patients Admitted to the Hospital. *Family Medicine and Medical Science Research*, **10**: 7.
- Zhao, W., Zha, X., Wang, N., Li, D., Li, A., dan Yu, S., 2021. Clinical Characteristics and Durations of Hospitalized Patients with COVID-19 in Beijing: A Retrospective Cohort Study. *Cardiovascular Innovations and Applications*, **6**: 33.